Amit Odelia1, Joffe Erel2, Perry Chava3, Herishanu Yair3, Sarid Nadav3, Lishner Michael4, Avivi Irit3. 1. Department of Hematology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel. amitodelia1@gmail.com. 2. Institute of Hematology, Davidoff Center, Rabin Medical Center, Beilinson Hospital, Petah-Tikva, Israel. 3. Department of Hematology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel. 4. Department of Medicine A, Meir Medical Center, Kfar Saba, Israel.
Abstract
INTRODUCTION: Due to the rarity of lymphoma during pregnancy, management guidelines are based upon evidence from retrospective studies and case reports. Here, we review the major dilemmas in the field and examine the approach of hemato-oncologists in Israel to the management of lymphoma in pregnancy. METHODOLOGY: We performed a literature search on the PubMed database using keywords for all papers on the subject from 1990-2014. The papers were reviewed by an expert panel who devised a questionnaire covering the main dilemmas. Sixty questionnaires were sent out. RESULTS: Non-contrast magnetic resonance imaging was the staging modality of choice. Chemoimmunotherapy was considered relatively safe beyond the first trimester except methotrexate (completed postpartum). Steroids or vinblastine were suggested by most as a reasonable 'bridging therapy' until the second trimester in Hodgkin lymphoma. The dosage of chemoimmunotherapy employed during pregnancy remained debatable; the majority recommended dosage according to actual pregnancy weight. Optimal timing for delivery was considered by most to be >35 weeks. Regarding approach to next pregnancy for patients in complete remission from diffuse large B-cell lymphoma, 69 % advised waiting 2 years but the majority advised 6-12 months for follicular lymphoma. DISCUSSION: Despite consensus regarding the safety of chemotherapy post first trimester, optimal dosage, central nervous system therapy, timing of delivery and approach to future pregnancies remain controversial, indicating a need for further collaborative research in this field.
INTRODUCTION: Due to the rarity of lymphoma during pregnancy, management guidelines are based upon evidence from retrospective studies and case reports. Here, we review the major dilemmas in the field and examine the approach of hemato-oncologists in Israel to the management of lymphoma in pregnancy. METHODOLOGY: We performed a literature search on the PubMed database using keywords for all papers on the subject from 1990-2014. The papers were reviewed by an expert panel who devised a questionnaire covering the main dilemmas. Sixty questionnaires were sent out. RESULTS: Non-contrast magnetic resonance imaging was the staging modality of choice. Chemoimmunotherapy was considered relatively safe beyond the first trimester except methotrexate (completed postpartum). Steroids or vinblastine were suggested by most as a reasonable 'bridging therapy' until the second trimester in Hodgkin lymphoma. The dosage of chemoimmunotherapy employed during pregnancy remained debatable; the majority recommended dosage according to actual pregnancy weight. Optimal timing for delivery was considered by most to be >35 weeks. Regarding approach to next pregnancy for patients in complete remission from diffuse large B-cell lymphoma, 69 % advised waiting 2 years but the majority advised 6-12 months for follicular lymphoma. DISCUSSION: Despite consensus regarding the safety of chemotherapy post first trimester, optimal dosage, central nervous system therapy, timing of delivery and approach to future pregnancies remain controversial, indicating a need for further collaborative research in this field.
Authors: Alistair E Ring; Ian E Smith; Alison Jones; Catherine Shannon; Eleni Galani; Paul A Ellis Journal: J Clin Oncol Date: 2005-06-20 Impact factor: 44.544
Authors: J G C van Hasselt; K van Calsteren; L Heyns; S Han; M Mhallem Gziri; J H M Schellens; J H Beijnen; A D R Huitema; F Amant Journal: Ann Oncol Date: 2014-04-08 Impact factor: 32.976
Authors: Kristel Van Calsteren; Liesbeth Heyns; Frank De Smet; Liesbet Van Eycken; Mina Mhallem Gziri; Willemijn Van Gemert; Michael Halaska; Ignace Vergote; Nelleke Ottevanger; Frédéric Amant Journal: J Clin Oncol Date: 2009-10-19 Impact factor: 44.544
Authors: Nabil Abdalla; Magdalena Bizoń; Robert Piórkowski; Paweł Stanirowski; Krzysztof Cendrowski; Włodzimierz Sawicki Journal: Biomed Res Int Date: 2017-05-24 Impact factor: 3.411